Figures S1-S8 from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Le résumé fourni par la source

Figure S1 shows a consort diagram of patients with pretreatment and postprogression circulating cell-free DNA samples sequenced; Figure S2 shows a bar graph showing that a significantly lower level of the serum marker CA-125 was found at study enrollment in patients with no TP53 or BRCA mutations detected in the pretreatment circulating cell-free DNA; Figure S3 shows a scatter plot showing significant correlation between mutant allele frequency of primary somatic BRCA and TP53 mutations detected in pretreatment circulating cell-free DNA; Figure S4 shows a graph indicating the location of deleterious BRCA mutations where reversion mutations were detected in pretreatment and postprogression circulating cell-free DNA; Figure S5 shows a scatter plot showing a significant correlation of mutation allele frequency for the detected primary deleterious BRCA mutations between two independent next-generation sequencing-based circulating cell-free DNA assays; Figure S6 shows a swimlane graph showing the duration on rucaparib treatment of patients with or without BRCA reversion mutations detected in pretreatment circulating cell-free DNA; Figure S7 shows a graph from a linear regression analysis between the sum of mutation allele frequency of BRCA reversion mutations from pretreatment plasma and rucaparib progression-free survival; Figure S8 shows a bar graph of changes in BRCA reversion allele frequencies detected in pretreatment and postprogression circulating cell-free DNA from one patient.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.